Vanguard Group’s CytRx Corp CYTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-304,476
Closed -$193K 4233
2019
Q1
$193K Buy
304,476
+4,799
+2% +$3.02K ﹤0.01% 3932
2018
Q4
$134K Sell
299,677
-494,046
-62% -$341K ﹤0.01% 3954
2018
Q3
$833K Sell
793,723
-6,103
-0.8% -$6.89K ﹤0.01% 3761
2018
Q2
$904K Buy
799,826
+45,021
+6% +$67.3K ﹤0.01% 3718
2018
Q1
$1.2M Buy
754,805
+120,170
+19% +$211K ﹤0.01% 3608
2017
Q4
$1.07M Sell
634,635
-254,105
-29% -$526K ﹤0.01% 3599
2017
Q3
$2.19M Buy
888,740
+84,886
+11% +$287K ﹤0.01% 3367
2017
Q2
$3.02M Buy
803,854
+281,646
+54% +$962K ﹤0.01% 3262
2017
Q1
$1.39M Buy
522,208
+65,033
+14% +$165K ﹤0.01% 3499
2016
Q4
$1.02M Buy
457,175
+77,685
+20% +$228K ﹤0.01% 3553
2016
Q3
$1.34M Buy
379,490
+5,705
+2% +$26.1K ﹤0.01% 3506
2016
Q2
$5M Buy
373,785
+23,591
+7% +$392K ﹤0.01% 2983
2016
Q1
$5.63M Buy
350,194
+16,049
+5% +$219K ﹤0.01% 2903
2015
Q4
$5.31M Buy
334,145
+3,699
+1% +$63.4K ﹤0.01% 2962
2015
Q3
$4.7M Buy
330,446
+47,935
+17% +$812K ﹤0.01% 2996
2015
Q2
$6.31M Buy
282,511
+8,050
+3% +$202K ﹤0.01% 2898
2015
Q1
$5.55M Sell
274,461
-751
-0.3% -$14K ﹤0.01% 2945
2014
Q4
$4.53M Sell
275,212
-15,439
-5% -$241K ﹤0.01% 2951
2014
Q3
$4.43M Sell
290,651
-22,818
-7% -$451K ﹤0.01% 2901
2014
Q2
$7.86M Buy
313,469
+104,154
+50% +$2.37M ﹤0.01% 2623
2014
Q1
$4.38M Buy
209,315
+100,515
+92% +$3.57M ﹤0.01% 2896
2013
Q4
$4.09M Buy
108,800
+37,490
+53% +$683K ﹤0.01% 2896
2013
Q3
$1.38M Hold
71,310
﹤0.01% 3276
2013
Q2
$856K Buy
+71,310
New +$1.05M ﹤0.01% 3346

Other funds holding CYTR

Vanguard Group's CYTR Position: Q2 2019 in Review

Vanguard Group sold out of CytRx Corp (CYTR) in Q2 2019, closing a stake of 304,476 shares — an estimated $193K sold.

Vanguard Group first reported a position in CYTR in Q2 2013 and held it in 24 quarters. The position peaked at $7.86M in Q2 2014. 5 funds tracked by Wall St. Rank hold CYTR as of Q2 2019.

  • Vanguard Group reported no remaining CytRx Corp position as of Q2 2019 after selling out during the quarter.
  • Vanguard Group sold 304,476 CytRx Corp shares in Q2 2019, an estimated $193K.
  • Vanguard Group first reported a position in CytRx Corp in Q2 2013 and held it in 24 quarters.
  • Vanguard Group's CytRx Corp position peaked at $7.86M in Q2 2014.
  • 5 funds tracked by Wall St. Rank held CytRx Corp as of Q2 2019.

Based on Vanguard Group's 13F filing for Q2 2019, filed 14 Aug 2019.